Skip to main content

Table 2 Common laboratory characteristics and their relavance with CA19–9 in patients with malignant and benign lesions

From: Dynamic change of serum CA19–9 levels in benign and malignant patients with obstructive jaundice after biliary drainage and new correction formulas

Laboratory characteristics

Malignant

Benign

P value

rs

P value

CA19–9, U/mL

474.4 (151.8–1325.5)

267.7 (141.9–639.9)

0.176

Total bilirubin, μmol/L

207.1 (107.1–340.3)

147.4 (111.3–219.9)

0.148

0.146

0.109

Alanine aminotransferase, U/L

120.5 (51.8–269.8)

135.0 (16.0–198.0)

0.49

0.068

0.456

Aspartate aminotransferase, U/L

543.0 (317.0–959.0)

500.5 (260.8–915.3)

0.805

0.086

0.399

Gamma-glutamyl transpeptidase, U/L

441.0 (284.0–682.3)

418.5 (234.8–603.8)

0.615

0.098

0.342

Alkaline phosphatase, U/L

128.0 (65.0–188.0)

103.0 (58.3–165.8)

0.444

0.066

0.519

Red blood cell count, × 1012

3.9 (3.4–4.3)

4.2 (3.6–4.6)

0.044

−0.075

0.416

White blood cell count, ×109

6.4 (5.1–7.9)

5.2 (4.1–8.0)

0.278

0.215

0.018

Neutrophil percentage, %

73.5 (64.5–80.4)

61.5 (55.9–74.6)

0.016

0.26

0.004

  1. †: Relavance with CA19–9 in malignant patients